ANAB
AnaptysBio, Inc.Healthcare·Biotechnology
$55.67
$2.4B market cap
Revenue
$133.8M
Free Cash Flow
$72.1M
Rev Growth
+0.0%
FCF Margin
53.9%
P/FCF
33.3x
EV/FCF
33.2x
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and AN
2-Year Price History
$59.71+274.1%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 25.6 | -34.0 | -34.6 | -52.9 | -25.9 | -25.9 | -0.0 | 286.5 | 277.4 | 28.7 | -50.0% | -1.6x | -- |
| Act | 2025-Q4 | 108.3 | 67.5 | 66.9 | 49.6 | 98.0 | 98.0 | -0.0 | 311.6 | 290.6 | 31.3 | 88.3% | 3.4x | -- |
Valuation & Metrics
Market Stats
Price$55.67
Market Cap$2.4B
Enterprise Value$2.4B
P/S Ratio17.9x
P/FCF33.3x
EV/FCF33.2x
FCF Margin (TTM)53.9%
FCF Yield3.0%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$133.8M
Net Income$-3.3M
Free Cash Flow$72.1M
Revenue Growth (YoY)+0.0%
EBITDA Margin25.0%
Net Margin-2.4%
FCF Margin53.9%
CapEx % of Revenue0.0%
SBC % of Revenue17.0%
ROIC19.2%
WC Change % Rev8.8%
Interest Coverage0.8x
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares4.5M
Days to Cover5.5
Change (vs Prior)+8.7%
Need at least 2 settlement dates for chart
Employees
Headcount136
Revenue / Employee$983,860
Gross Profit / Employee$1,773,404
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
48.8%(+24.0% YoY)
188 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
10.5%(+6.7% YoY)
10 filers
Vanguard, iShares, SPDR
Market makers
0.4%(+0.4% YoY)
7 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | $437M | $19.20 | +$0 | +$0 | -5.5% | $2.34B |
| BlackRock, Inc.Passive | $93.2M | $20.44 | −$2.0M | −$27.5M | -0.2% | $5.69T |
| TANG CAPITAL MANAGEMENT LLC | $73.8M | $12.49 | −$45K | −$11.9M | -5.8% | $1.93B |
| MORGAN STANLEY | $55.1M | $14.54 | −$1.5M | +$27.1M | -0.3% | $1.65T |
| STATE STREET CORPPassive | $55.0M | $15.50 | −$2.3M | +$7.3M | -0.2% | $2.89T |
| Affinity Asset Advisors, LLC | $52.1M | $34.77 | +$18.3M | +$52.1M | +0.5% | $1.60B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $47.3M | $36.97 | +$31.5M | +$47.3M | — | $4.04T |
| Palo Alto Investors LP | $35.4M | $14.91 | −$1.9M | −$21.2M | -3.0% | $586M |
| 683 Capital Management, LLC | $34.7M | $17.21 | −$854K | +$23.8M | -2.3% | $1.02B |
| D. E. Shaw & Co., Inc. | $32.1M | $24.99 | −$3.4M | +$24.9M | -0.3% | $118.02B |
| First Light Asset Management, LLC | $31.4M | $12.91 | −$3.0M | −$226M | -10.4% | $1.12B |
| Sanofi | $30.4M | $8.83 | +$0 | +$0 | +1.7% | $336M |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $28.9M | $21.24 | +$1.9M | +$1.6M | +2.3% | $1.61T |
| VANGUARD PORTFOLIO MANAGEMENT LLCPassive | $28.8M | $36.97 | +$19.2M | +$28.8M | — | $1.91T |
| BANK OF AMERICA CORP /DE/ | $27.8M | $18.37 | +$13.7M | −$35.7M | -0.1% | $1.36T |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $27.3M | $23.07 | −$2.5M | +$27.3M | +0.1% | $184.72B |
| MILLENNIUM MANAGEMENT LLC | $26.4M | $18.75 | −$12.5M | +$25.4M | -0.5% | $127.40B |
| FMR LLC | $26.2M | $19.92 | +$16.5M | −$79.4M | -0.0% | $1.89T |
| TWO SIGMA INVESTMENTS, LP | $25.8M | $21.91 | +$7.7M | +$11.0M | -0.9% | $117.03B |
| FEDERATED HERMES, INC. | $20.2M | $18.86 | +$2.4M | +$19.7M | -1.1% | $61.33B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BEARISH
Holders
-2.29%
avg per quarter
Holders (ex-self)
-2.62%
excl. this stock
Buyers (this Q)
+0.32%
91 buyers · $0.29B in
Sellers (this Q)
+0.94%
84 sellers · $0.15B out
alpha coverage: 95% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
+20.6%
how holders react when this stock falls
On quiet Qs
+18.1%
−10% to +10% baseline
On rallies (+10%+)
-6.6%
how they react when this stock rises
Holders' portfolio flow this Q
+2.5%
inflows — adds are organic
Sellers' portfolio flow this Q
-6.7%
Sellers shed AUM broadly — partly forced.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-3.4%
Holder mid (any stock)
-3.6%
Holder rally (any stock)
-5.1%
Biggest decreases this quarter
MILLENNIUM MANAGEMENT LLC−$12.5Mα-0.5Woodline Partners LP−$5.8Mα-0.1D. E. Shaw & Co., Inc.−$3.4Mα-0.3First Light Asset Management, LLC−$3.0Mα-10.4ARROWSTREET CAPITAL, LIMITED PARTNERSHIP−$2.5Mα+0.1GOLDMAN SACHS GROUP INC−$2.4Mα-0.2STATE STREET CORP−$2.3Mα-0.2BlackRock, Inc.−$2.0Mα-0.2Palo Alto Investors LP−$1.9Mα-3.0MORGAN STANLEY−$1.5Mα-0.3
New buyers this quarter
Top-5 holders · 46.1%
EcoR1 Capital, LLC--
BlackRock, Inc.--
TANG CAPITAL MANAGEMENT LLC--
MORGAN STANLEY--
STATE STREET CORP--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
EcoR1 Capital, LLC7.9MFMR LLC473KPoint72 Asset Management, L.P.55KTANG CAPITAL MANAGEMENT LLC1.3MFirst Light Asset Management, LLC565KFrazier Life Sciences Management, L.P.—FEDERATED HERMES, INC.364KMORGAN STANLEY994KAffinity Asset Advisors, LLC940KMILLENNIUM MANAGEMENT LLC476K
Related Stocks
Investors who own this also own
Stocks held by the same active managers as this one, ranked by score — how much more often these appear together than random chance (1× = baseline). Excludes index ETFs and market makers; minimum 3 shared holders.
| Ticker | Name | Co-holders | Score |
|---|---|---|---|
| CNTA | Centessa Pharmaceuticals plc | 3 | 76.46× |
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (8 analysts)$73.383180.0%
Last Year (19 analysts)$71.112770.0%
Current Price$55.67
Analyst Ratings
16
6
Buy: 16Hold: 6Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$10.58M
29 txns · 9 insiders · 240,030 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-03-30 | SELL | Schmid John P. | director | 20,645 | $56.11 | $1.16M | $1.77M |
| 2026-03-27 | SELL | Faga Daniel | director, officer: President, CEO | 17,679 | $61.61 | $1.09M | $30.56M |
| 2026-02-11 | SELL | LOUMEAU ERIC J | officer: CHIEF LEGAL OFFICER | 10,000 | $54.00 | $540K | $693K |
| 2026-01-15 | SELL | Marquet Magda | director | 11,000 | $48.23 | $531K | $479K |
| 2026-01-08 | SELL | Faga Daniel | director, officer: President, CEO | 14,281 | $44.71 | $639K | $21.43M |
| 2026-01-08 | SELL | LOUMEAU ERIC J | officer: CHIEF LEGAL OFFICER | 2,210 | $44.71 | $99K | $574K |
| 2026-01-08 | SELL | Lizzul Paul F. | officer: Chief Medical Officer | 3,650 | $44.71 | $163K | $1.88M |
| 2026-01-08 | SELL | MULROY DENNIS | officer: CHIEF FINANCIAL OFFICER | 2,515 | $44.71 | $112K | $977K |
| 2026-01-07 | SELL | Faga Daniel | director, officer: President, CEO | 9,202 | $45.11 | $415K | $21.06M |
| 2026-01-07 | SELL | LOUMEAU ERIC J | officer: CHIEF LEGAL OFFICER | 9,639 | $45.56 | $439K | $417K |
| 2026-01-07 | SELL | Lizzul Paul F. | officer: Chief Medical Officer | 2,235 | $45.11 | $101K | $1.68M |
| 2026-01-07 | SELL | MULROY DENNIS | officer: CHIEF FINANCIAL OFFICER | 1,908 | $45.11 | $86K | $797K |
| 2026-01-05 | SELL | MULROY DENNIS | officer: CHIEF FINANCIAL OFFICER | 3,363 | $43.26 | $145K | $620K |
| 2026-01-05 | SELL | Lizzul Paul F. | officer: Chief Medical Officer | 4,219 | $43.26 | $183K | $1.44M |
| 2026-01-05 | SELL | LOUMEAU ERIC J | officer: CHIEF LEGAL OFFICER | 2,983 | $43.26 | $129K | $573K |
| 2026-01-05 | SELL | Faga Daniel | director, officer: President, CEO | 15,309 | $43.26 | $662K | $19.82M |
| 2025-12-23 | SELL | Ware J. Anthony | director | 3,900 | $49.58 | $193K | $477K |
| 2025-12-22 | SELL | LOUMEAU ERIC J | officer: CHIEF LEGAL OFFICER | 10,000 | $51.00 | $510K | $456K |
| 2025-12-22 | SELL | Lizzul Paul F. | officer: Chief Medical Officer | 1,500 | $50.00 | $75K | $1.35M |
| 2025-12-22 | SELL | MULROY DENNIS | officer: CHIEF FINANCIAL OFFICER | 10,000 | $50.00 | $500K | $470K |
Order Flow (FINRA, ~3w lag)
29.4%retail+2.0pp
11.6%dark-4.4pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
ANAPTYSBIO, INC.: High-Yield Royalty Monetization and Aggressive Buybacks Masking a Fragile Balance Sheet
Overall Risk
7/10
Fraud
3/10
Dilution
5/10
Insolvency
6/10
Earnings Overstated
8/10
Hidden Liabilities
4/10
Legal
5/10
Audit Warnings
2/10
Hidden Upside
6/10
Contextually Acceptable
4/10